The effect of anticoagulant therapy in primary and anorectic drug- induced pulmonary hypertension

Chest

Volumn 112, Issue 3, 1997, Pages 714-721

  Frank, H ^a   Mlczoch, J ^a   Huber, K ^a   Schuster, E ^a   Gurtner, H P ^a   Kneussl, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anticoagulant therapy; Drug induced pulmonary hypertension; Exogenous pulmonary hypertension; Long term survival; Primary pulmonary hypertension

Indexed keywords

AMINOREX; ANOREXIGENIC AGENT; ANTICOAGULANT AGENT; PHENPROCOUMON; WARFARIN;

ADOLESCENT; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; SURVIVAL TIME;

EID: 0030813510     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.112.3.714     Document Type: Article

References (34)

1. Gurtner HP. Aminorex pulmonary hypertension Fishman AP The pulmonary circulation 1990 University of Pennsylvania Press Philadelphia 397 411
2. Jones DK Higenbottam TW Wallwork J. Treatment of primary pulmonary hypertension with intravenous epoprostenol Br Heart J 57 1987 270 278
3. Rich S Brundage BH. High dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy Circulation 76 1987 135 141
4. Cohen M Fuster V Edwards W. Anticoagulation in the treatment of pulmonary hypertension Fishman AP The pulmonary circulation 1990 University of Pennsylvania Press Philadelphia 501 510
5. Rich S Kaufmann E Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension n Engl J Med 327 1992 76 81
6. Gurtner HP. Chronische pulmonale hypertonie vascularen ursprungs, plexogene pulmonale arteriopathie und der appetitzügler aminorex: nachlese zu einer epidemie Schweiz Med Wochenschr 115 1985 779 782
7. Higenbottam T. Primary pulmonary hypertension BMJ 293 1986 1456 1457
8. Mlczoch J. Drug and dietary induced pulmonary hypertension Weir EK Reeves JT Pulmonary hypertension 1984 Futura Mount Kisco ny 341 359
9. Mlczoch J. Evolution of primary pulmonary hypertension Prog Respir Res 20 1985 176 181
10. Haworth SG. Primary pulmonary hypertension Br Heart J 49 1983 517 521
11. Wood P. Diseases of the heart and circulation 2nd ed. 1956 Eyre & Spottiswoode London
12. Wilcken P. Anticoagulant treatment of obliterative pulmonary hypertension Lancet 2 1960 781 783
13. Fuster V Steele PM Edwards WD Primary pulmonary hypertension: natural history and the importance of thrombosis Circulation 70 1984 580 587
14. Robin ED. The kingdom of the near-dead: the shortened unnatural life history of primary pulmonary hypertension Chest 92 1987 330 334
15. Bourdillon PDV Oakley CM. Regression of primary pulmonary hypertension Br Heart J 38 1976 264 270
16. Fujii A Rabinovitch M Matthews EC. A case of spontaneous resolution of idiopathic pulmonary hypertension Br Heart J 46 1981 574 577
17. Gurtner HP Lepine JP Mordasini RC. Long term follow up of pulmonary hypertension developing after the intake of the anorexigen aminorex Chazov EI Smirnov VN Oganov RG Cardiology 1984 Plenum Publishing Co New York 1205 1215
18. Mlczoch J Probst P Szeless ST Primary pulmonary hypertension: follow up of patients with and without anorectic drug intake Cor Vasa 22 1980 251 257
19. Gurtner HP. Pulmonary hypertension, plexogenic pulmonary arteriopathy and the appetite depressant drug aminorex: post or propter? Bull Eur Physiopathol Respir 15 1979 897 923
20. Rich S. Primary pulmonary hypertension Prog Cardiovasc Dis 31 1988 205 238
21. Eisenberg PR Lucore C Kaufman L Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension Circulation 82 1990 841 847
22. Huber K Beckmann R Frank H Variables of coagulation and fibrinolysis in patients with primary or secondary pulmonary hypertension [abstract] Eur Heart J 9 suppl A 1988 286
23. Rich S Brundage BH. Primary pulmonary hypertension: current update JAMA 251 1984 2252 2254
24. Glanville AR Burke CM Theodore J Primary pulmonary hypertension: length of survival in patients referred for heart-lung transplantation Chest 91 1987 675 681
25. Suarez LD Scandro EE Llera JJ Long-term follow-up in primary pulmonary hypertension Br Heart J 41 1979 702 708
26. Rich S Levy PS. Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension Am J Med 76 1984 573 578
27. Nielsen NC Fabricius J. Primary pulmonary hypertension, with special reference to prognosis Acta Med Scand 170 1961 731 746
28. Rozkovec A Montanes P Oakley CM. Factors that influence the outcome in primary pulmonary hypertension Br Heart J 55 1986 449 458
29. Rubin LJ Peter RH. Oral hydralazine therapy for primary pulmonary hypertension N Engl J Med 302 1980 69 73
30. Packer M Greenberg B Massie B Deleterious effects of hydralazine in patients with primary pulmonary hypertension N Engl J Med 306 1982 1326 1331
31. Packer M Medina N Yushak M. Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease J Am Coll Cardiol 4 1984 890 901
32. Rich S Ganz R Levy PS. Comparative effects of hydralazine, nifedipine and amrinone in primary pulmonary hypertension Am J Cardiol 52 1983 1104 1107
33. Rich S Martinez J Lam W Reassessment of the effects of vasodilator drugs in primary pulmonary hypertension: guidelines for determining a pulmonary vasodilator response Am Heart J 105 1983 119 127
34. Frank H Mlczoch J Lang I Influence of warfarin therapy in primary pulmonary hypertension: pulmonary blood vessels in lung disease Prog Respir Res 26 1990 119 124